These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

61 related items for PubMed ID: 8793049

  • 21. Speed and accuracy on tests of executive function in obsessive-compulsive disorder.
    Roth RM, Baribeau J, Milovan DL, O'Connor K.
    Brain Cogn; 2004 Apr; 54(3):263-5. PubMed ID: 15050790
    [Abstract] [Full Text] [Related]

  • 22. Induction of depersonalization by the serotonin agonist meta-chlorophenylpiperazine.
    Simeon D, Hollander E, Stein DJ, DeCaria C, Cohen LJ, Saoud JB, Islam N, Hwang M.
    Psychiatry Res; 1995 Sep 29; 58(2):161-4. PubMed ID: 8570768
    [Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26. Unwanted erections in obsessive-compulsive disorder.
    Warwick HM, Salkovskis PM.
    Br J Psychiatry; 1990 Dec 29; 157():919-21. PubMed ID: 2289105
    [Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28. Advances in obsessive-compulsive disorder.
    Hart BL.
    Neuropsychopharmacology; 1991 Aug 29; 5(1):19; discussion 21-2. PubMed ID: 1930608
    [No Abstract] [Full Text] [Related]

  • 29. Sodium lactate infusion in fibromyalgia patients.
    Tanum L, Malt UF.
    Biol Psychiatry; 1995 Oct 15; 38(8):559-61. PubMed ID: 8562669
    [No Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31. Are prepared fears less severe, but more resistant to treatment?
    Merckelbach H, van den Hout MA, Hoekstra R, van Oppen P.
    Behav Res Ther; 1988 Oct 15; 26(6):527-30. PubMed ID: 3240237
    [No Abstract] [Full Text] [Related]

  • 32. Naloxone, arousal, and the patient's best interests.
    Hardy PA.
    Lancet; 1981 Nov 07; 2(8254):1052. PubMed ID: 6118510
    [No Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35. Psychopharmacological Treatment of Obsessive-Compulsive Disorder (OCD).
    Del Casale A, Sorice S, Padovano A, Simmaco M, Ferracuti S, Lamis DA, Rapinesi C, Sani G, Girardi P, Kotzalidis GD, Pompili M.
    Curr Neuropharmacol; 2019 Nov 07; 17(8):710-736. PubMed ID: 30101713
    [Abstract] [Full Text] [Related]

  • 36. Buprenorphine augmentation in the treatment of refractory obsessive-compulsive disorder.
    Liddell MB, Aziz V, Briggs P, Kanakkehewa N, Rawi O.
    Ther Adv Psychopharmacol; 2013 Feb 07; 3(1):15-9. PubMed ID: 23983988
    [Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39. The relationship between impulse-control disorders and obsessive-compulsive disorder: a current understanding and future research directions.
    Potenza MN, Koran LM, Pallanti S.
    Psychiatry Res; 2009 Nov 30; 170(1):22-31. PubMed ID: 19811840
    [Abstract] [Full Text] [Related]

  • 40. Role of atypical opiates in OCD. Experimental approach through the study of 5-HT(2A/C) receptor-mediated behavior.
    Rojas-Corrales MO, Gibert-Rahola J, Mico JA.
    Psychopharmacology (Berl); 2007 Feb 30; 190(2):221-31. PubMed ID: 17102981
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 4.